GlassScriptPhysician profile
Karen E Genter
NPI 1790407260
$1,531.85
in general payments reported to CMS, 2019-2025
14 companies · $649 in 2025
The $649 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $260 · 2023: $481 · 2024: $142 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $364.78 | 2022-2025 | |
| Solventum Corporation | $179.76 | 2025 | Activ.A.C. |
| Hollister Incorporated | $170.39 | 2023-2025 | New Image, Premier |
| Medtronic, INC. | $158.04 | 2023 | Interstim |
| Smith+Nephew, INC. | $140.15 | 2025 | Collagenase Santyl, Allevyn Heel 10.5cm X 13.5cm Ctn 5 |
| Amgen INC. | $124.74 | 2023 | Repatha |
| Novo Nordisk INC | $119.32 | 2022 | |
| Astellas Pharma US INC | $104.31 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $46.26 | 2025 | Rexulti |
| Molnlycke Health Care US, LLC | $45.64 | 2023 | Mepilex Border Sacrum, Mepilex, Mepilex Border Em |
| Coloplast Corp | $32.53 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.55 | 2022 | |
| Alkermes, INC. | $14.87 | 2025 | Aristada, Lybalvi |
| Lilly USA, LLC | $14.51 | 2025 | Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Genter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.